- Home
- SPFI vs CVAC Comparison
SPFI vs CVAC Comparison
Compare SPFI & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPFI
- CVAC
- Stock Information
- Founded
- SPFI 1941
- CVAC 2000
- Country
- SPFI United States
- CVAC Germany
- Employees
- SPFI N/A
- CVAC N/A
- Industry
- SPFI Major Banks
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- SPFI Finance
- CVAC Health Care
- Exchange
- SPFI Nasdaq
- CVAC Nasdaq
- Market Cap
- SPFI 647.7M
- CVAC 643.9M
- IPO Year
- SPFI 2019
- CVAC 2020
- Fundamental
- Price
- SPFI $36.01
- CVAC $3.05
- Analyst Decision
- SPFI Buy
- CVAC Hold
- Analyst Count
- SPFI 2
- CVAC 3
- Target Price
- SPFI $33.50
- CVAC $10.00
- AVG Volume (30 Days)
- SPFI 33.3K
- CVAC 549.6K
- Earning Date
- SPFI 01-24-2025
- CVAC 11-12-2024
- Dividend Yield
- SPFI 1.68%
- CVAC N/A
- EPS Growth
- SPFI N/A
- CVAC N/A
- EPS
- SPFI 2.56
- CVAC N/A
- Revenue
- SPFI $183,911,000.00
- CVAC $70,565,734.00
- Revenue This Year
- SPFI N/A
- CVAC $738.59
- Revenue Next Year
- SPFI $6.18
- CVAC N/A
- P/E Ratio
- SPFI $13.94
- CVAC N/A
- Revenue Growth
- SPFI N/A
- CVAC 75.11
- 52 Week Low
- SPFI $24.05
- CVAC $2.22
- 52 Week High
- SPFI $40.91
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- SPFI 42.35
- CVAC 53.82
- Support Level
- SPFI $31.26
- CVAC $2.83
- Resistance Level
- SPFI $36.62
- CVAC $3.06
- Average True Range (ATR)
- SPFI 1.55
- CVAC 0.19
- MACD
- SPFI -0.43
- CVAC -0.02
- Stochastic Oscillator
- SPFI 51.97
- CVAC 42.05
About SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has two reportable segments: banking and insurance.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.